Search Results - "Tracewell, William G"

Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement by Mellion, Michelle L., Ronco, Lucienne, Berends, Cecile L., Pagan, Lisa, Brooks, Sander, Esdonk, Michiel J., Brummelen, Emilie M. J., Odueyungbo, Adefowope, Thompson, Lorin A., Hage, Michelle, Badrising, Umesh A., Raines, Shane, Tracewell, William G., Engelen, Baziel, Cadavid, Diego, Groeneveld, Geert J.

“…Aims Evaluate safety, tolerability, pharmacokinetics (PK) and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD)…”
Get full text

Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects by Schneider, Frank, Erisson, Lavi, Beygi, Hooman, Bradbury, Margaret, Cohen‐Barak, Orit, Grachev, Igor D., Guzy, Serge, Loupe, Pippa S., Levi, Micha, McDonald, Mirna, Savola, Juha‐Matti, Papapetropoulos, Spyros, Tracewell, William G., Velinova, Maria, Spiegelstein, Ofer

“…Aims SD‐1077, a selectively deuterated precursor of dopamine (DA) structurally related to L‐3,4‐dihydroxyphenylalanine (L‐DOPA), is under development for…”
Get full text

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis by Geller, David E, Pitlick, William H, Nardella, Pasqua A, Tracewell, William G, Ramsey, Bonnie W

“…To describe the pharmacokinetics and bioavailability of inhaled tobramycin (TOBI; Chiron Corporation; Seattle, WA), 300-mg dose, delivered by a nebulizer (PARI…”
Get more information

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial by Tawil, Rabi, Wagner, Kathryn R, Hamel, Johanna I, Leung, Doris G, Statland, Jeffrey M, Wang, Leo H, Genge, Angela, Sacconi, Sabrina, Lochmüller, Hanns, Reyes-Leiva, David, Diaz-Manera, Jordi, Alonso-Perez, Jorge, Muelas, Nuria, Vilchez, Juan J, Pestronk, Alan, Gibson, Summer, Goyal, Namita A, Hayward, Lawrence J, Johnson, Nicholas, LoRusso, Samantha, Freimer, Miriam, Shieh, Perry B, Subramony, S H, van Engelen, Baziel, Kools, Joost, Leinhard, Olof Dahlqvist, Widholm, Per, Morabito, Christopher, Moxham, Christopher M, Cadavid, Diego, Mellion, Michelle L, Odueyungbo, Adefowope, Tracewell, William G, Accorsi, Anthony, Ronco, Lucienne, Gould, Robert J, Shoskes, Jennifer, Rojas, Luis Alejandro, Jiang, John G

“…Facioscapulohumeral muscular dystrophy is a hereditary progressive myopathy caused by aberrant expression of the transcription factor DUX4 in skeletal muscle…”
Get full text

pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment by Sweeney, Christopher J, Takimoto, Chris, Wood, Leslie, Porter, Jennifer M, Tracewell, William G, Darwish, Mona, D'Andrea, Denise M, Remick, Scot C

“…Purpose This study evaluated the pharmacokinetic and safety profiles of arsenic trioxide given twice per week in adult cancer patients with advanced…”
Get full text

Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects by Teo, Steve K., Scheffler, Michael R., Kook, Karin A., Tracewell, William G., Colburn, Wayne A., Stirling, David I., Thomas, Steve D.

“…Thalidomide is approved in the United States for treating erythema nodosum leprosum, a complication of leprosy. The present study determined the single‐dose…”
Get full text

Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma by Marley, Kevin, Helfand, Stuart C, Simpson, Jennifer, Mata, John E, Tracewell, William G, Brownlee, Lisa, Bracha, Shay, Séguin, Bernard

“…Osteosarcoma in dogs and humans share many similarities and the dog has been described as an excellent model to study this disease. The median survival in dogs…”
Get full text

Clinical pharmacokinetics of thalidomide by TEO, Steve K, COLBURN, Wayne A, TRACEWELL, William G, KOOK, Karin A, STIRLIN, David I, JAWORSKY, Markian S, SCHEFFLER, Michael A, THOMAS, Steve D, LASKIN, Oscar L

“…Thalidomide is a racemic glutamic acid derivative approved in the US for erythema nodosum leprosum, a complication of leprosy. In addition, its use in various…”
Get full text

Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women by Teo, Steve K., Scheffler, Michael R., Kook, Karin A., Tracewell, William G., Colburn, Wayne A., Stirling, David I., Thomas, Steve D.

“…The effect of food on the oral pharmacokinetics of thalidomide and the relative bioavailability of two oral thalidomide formulations were determined in an open…”
Get full text

Pharmacokinetics and pharmacodynamics of hydroxyurea by GWILT, P. R, TRACEWELL, W. G

“…Hydroxyurea is used in the treatment of various forms of cancer, sickle-cell anaemia and HIV infection. Oral absorption of the drug is virtually complete, the…”
Get full text

Effect of colesevelam on lovastatin pharmacokinetics by Donovan, JM, Kisicki, JC, Stiles, MR, Tracewell, WG, Burke, SK

“…OBJECTIVE: To assess potential interactions of colesevelam hydrochloride and lovastatin in healthy volunteers when lovastatin alone was administered with…”
Get full text

The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans by GWILT, P. R, NAHHAS, R. R, TRACEWELL, W. G

“…The article reviews the effect of diabetes on the pharmacokinetics and pharmacodynamics of drugs in humans. For most drugs which cross the gastrointestinal…”
Get full text

Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects by Teo, Steve K, Scheffler, Michael R, Kook, Karin A, Tracewell, William G, Colburn, Wayne A, Stirling, David I, Thomas, Steve D

“…Thalidomide is approved in the United States for treating erythema nodosum leprosum, a complication of leprosy. The present study determined the single-dose…”
Get full text

Population pharmacokinetics of hydroxyurea in cancer patients by TRACEWELL, W. G, TRUMP, D. L, VAUGHAN, W. P, SMITH, D. C, GWILT, P. R

“…The pharmacokinetics of hydroxyurea (HU) were investigated in cancer patients after intravenous infusion or oral administration. On the basis of the minimal…”
Get full text

Population Pharmacokinetics of Glyburide in Patients with Well-Controlled Diabetes by Tracewell, William G., Stalker, Dennis J., Maloley, Pierre A., Gallagher, Thomas F., Gwilt, Peter R.

“…Study Objectives. To investigate glyburide pharmacokinetics in patients with well‐controlled noninsulin‐dependent diabetes mellitus (NIDDM), and test the…”
Get full text

Nonlinear disposition of hydroxyurea by Tracewell, W G, Vaughan, W P, Gwilt, P R

Get more information

Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion by Iversen, P L, Mata, J, Tracewell, W G, Zon, G

“…An antisense phosphorothioate oligodeoxynucleotide 27-mer complementary to the rev gene mRNA of the human immunodeficiency virus (HIV-1) was administered to…”
Get more information

Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swine by Mata, J E, Jackson, J D, Joshi, S S, Tracewell, W G, Pirruccello, S J, Murphy, B J, Bishop, M R, Iversen, P L

“…A short phosphorothioate oligodeoxynucleotide telomere mimic with the sequence 5'-d(TTAGGG)-3', TAG-6, has been shown to inhibit telomerase activity and have…”
Get more information